Telehealth Ketamine for Anxiety: Evidence, Applications, and Platform Support

Telehealth ketamine for anxiety is available through most major online ketamine clinics, and it is most often prescribed for generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, and anxiety that occurs alongside treatment-resistant depression. The evidence supporting ketamine for anxiety is real but earlier-stage than the evidence for depression: most anxiety trials are small, several are open-label rather than placebo-controlled, and researchers still have limited data on how long the anxiolytic effects last. Ketamine works differently than the standard anxiety treatments, SSRIs, SNRIs, benzodiazepines, and cognitive behavioral therapy (CBT), because it acts on the brain's glutamate system rather than serotonin or GABA. That mechanism is part of why some patients notice anxiety relief within hours rather than the weeks typically required for SSRIs to take effect. This guide covers what the anxiety-specific research shows, which anxiety diagnoses are most likely to respond, how benzodiazepine use factors into treatment, and what to look for in a telehealth platform's anxiety support.

What the Research Shows About Ketamine for Anxiety

According to the National Institute of Mental Health, an estimated 19.1% of U.S. adults experience an anxiety disorder in a given year, making anxiety disorders the most common category of mental illness in the country. (National Institute of Mental Health) Despite that prevalence, a meaningful share of patients do not get adequate relief from first-line treatments, and ketamine has become a second-line option for some of them, though the anxiety research base is smaller than the depression research base.

Key Findings

• Several open-label studies and small randomized trials have shown rapid anxiolytic (anxiety-reducing) effects from ketamine, sometimes within hours of treatment.
• Ketamine's proposed mechanism for anxiety overlaps with its antidepressant mechanism. According to StatPearls, ketamine acts primarily as an NMDA receptor antagonist, which triggers downstream glutamate signaling, brain-derived neurotrophic factor (BDNF) release, and rapid changes in connectivity between fear-processing brain regions and the prefrontal cortex. (StatPearls)
• Ketamine's efficacy for anxiety appears strongest when anxiety is comorbid with depression, which describes the majority of treatment-resistant cases.
• Generalized anxiety disorder, social anxiety disorder, and treatment-resistant panic disorder have each been studied, though sample sizes remain small.

Limitations of the Evidence

• Most anxiety trials involve fewer than 50 patients.
• Few are randomized, double-blind, placebo-controlled trials, the study design considered most reliable for establishing efficacy.
• The durability of anxiolytic effects is less well-characterized than for depression, so it is unclear how long a single course of treatment lasts for anxiety specifically.
• Anxiety disorders are heterogeneous, meaning results for GAD may not generalize to social anxiety, panic disorder, or obsessive-compulsive disorder (OCD), which is classified separately from anxiety disorders but shares some overlapping features and treatment considerations.

Patients considering ketamine specifically for an anxiety diagnosis without comorbid depression should ask their provider directly about the strength of the evidence for that specific diagnosis, since research support varies considerably by anxiety subtype.

Anxiety Disorders That May Respond to Ketamine

Generalized Anxiety Disorder (GAD)

GAD is characterized by persistent, difficult-to-control worry across multiple areas of life, such as work, health, and relationships. Some evidence supports a ketamine response in GAD, and the proposed mechanism involves reducing the excessive neural excitation thought to underlie pathological worry. Several telehealth platforms accept GAD as a treatment indication.

Social Anxiety Disorder (SAD)

Social anxiety disorder has limited but growing evidence for ketamine response. The proposed mechanism may involve reduced sensitivity to social threat cues and increased willingness to approach previously feared social situations. Integration work that includes behavioral practice in social settings between sessions may enhance the benefit.

Panic Disorder

Some patients with panic disorder, particularly those with agoraphobia limiting daily functioning, have responded to ketamine. Reduced baseline anxiety and the neuroplastic window that follows a session, during which the brain may be more receptive to forming new, non-panic associations with previously avoided situations, are proposed mechanisms.

Anxiety With Comorbid Depression

This is where ketamine's evidence for anxiety is most solid. Most patients with treatment-resistant anxiety also have significant depression, and the well-established antidepressant evidence likely captures meaningful anxiolytic benefit in these comorbid presentations. For a deeper look at how ketamine is used in treatment-resistant depression, see treatment-resistant depression: next steps. Anxiety can also occur alongside bipolar disorder, which requires additional screening before ketamine treatment; see telehealth ketamine for bipolar disorder for that specific consideration.

Special Considerations for Anxiety Patients

Patients with anxiety disorders often feel significant anticipatory anxiety about the ketamine experience itself, since the unknown quality of an altered state can activate anxiety rather than resolve it. The checklist above outlines steps that can reduce that anticipatory anxiety before a session.

The Risk of Paradoxical Anxiety During Sessions

Some patients with anxiety disorders experience an initial heightening of anxiety as ketamine takes effect, before the dissociative state resolves it. Your provider should know your anxiety history so the dose can be titrated appropriately and so support is available if needed. Having a clear plan for what to do if you become acutely anxious during a session, such as speaking aloud to your sitter or using a grounding phrase, reduces the risk of a difficult experience. If a session does produce an adverse reaction, report it to your provider; see reporting adverse events for how that process typically works.

Integration Focus for Anxiety

Integration after ketamine sessions for anxiety should specifically address what patterns or beliefs underlie the anxiety, what the session revealed about how you relate to fear or uncertainty, small behavioral commitments toward previously avoided situations while the neuroplastic window is open, and somatic practices such as breathwork or progressive muscle relaxation to support nervous system regulation.

Anxiety and Benzodiazepine Use

Many patients with anxiety disorders take benzodiazepines, and this is an important interaction to discuss with a ketamine provider before starting treatment. Benzodiazepines can blunt ketamine's antidepressant and anxiolytic effects, and taking a benzodiazepine at the time of a session may also affect the quality of the dissociative experience. Some providers recommend reducing benzodiazepine use before a treatment course, but that decision belongs to the prescribing provider, not the patient alone, given the withdrawal risks described above.

Which Telehealth Platforms Treat Anxiety?

Nearly all major telehealth ketamine platforms list anxiety as a treatment indication alongside depression. Treating complex or treatment-resistant anxiety, however, may benefit from platforms with stronger integration support:

• Therapist-integration platforms tend to work best for anxiety that is comorbid with significant trauma, or for patients whose anxiety benefits from ongoing licensed therapist integration.
• Comprehensive program platforms that use health coaching models can address anxiety-specific patterns directly in integration sessions.
• Subscription session platforms typically offer broad anxiety treatment experience and app-based tools that may include anxiety-specific content, though with less individualized integration support.

Session structure and cost also vary by platform model; see monthly subscription vs. per-session pricing for how that affects the total cost of an anxiety treatment course, and does Medicare cover ketamine therapy for coverage considerations.

Monitoring Anxiety Outcomes

Your provider should track anxiety severity using a validated measure. The GAD-7 (a 7-item generalized anxiety disorder scale) is the standard tool used across most telehealth ketamine platforms. Ask your provider to administer it at baseline and at regular intervals so you have objective data on your response. Subjective anxiety often fluctuates day to day, and validated scale scores help distinguish real improvement from short-term relief, and help identify when a treatment plan needs adjustment.

Sources

This article draws on the following reference sources for background on ketamine's mechanism and anxiety prevalence:

• StatPearls: Ketamine, a clinical reference on ketamine pharmacology and mechanisms of action
• PubChem: Ketamine Compound Summary, the NCBI chemical database entry for ketamine
• National Institute of Mental Health: Anxiety Disorders statistics
• World Health Organization: Depression Fact Sheet